FDA authorizes new Moderna, Pfizer boosters for younger age groups

The Food and Drug Administration amended the emergency use authorizations of the Moderna (MRNA) COVID-19 Vaccine, Bivalent and the Pfizer (PFE) – BioNTech (BNTX) COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups. The Moderna COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to six years of age. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to five years of age.